Luqmani Y. Mechanisms of drug resistance in cancer chemotherapy. Med Principles Pract. 2005;14(Suppl 1):35–48.

Article  Google Scholar 

Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer drug Resist. 2019;2(2):141.

PubMed  PubMed Central  Google Scholar 

Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859–76.

Article  PubMed  CAS  Google Scholar 

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genom. 2011;4:1–14.

Article  Google Scholar 

Meng X, Bai X, Ke A, Li K, Lei Y, Ding S, Dai D. Long non-coding RNAs in Drug Resistance of Gastric Cancer: Complex mechanisms and potential clinical applications. Biomolecules. 2024;14(6):608.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13(3):326–46.

Article  PubMed  CAS  Google Scholar 

Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers. 2021;13(17):4363.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Groth-Pedersen L, Jäättelä M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 2013;332(2):265–74.

Article  PubMed  CAS  Google Scholar 

Riquelme I, Letelier P, Riffo-Campos AL, Brebi P, Roa JC. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17(3):424.

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–64.

Article  PubMed  CAS  Google Scholar 

Pavlíková L, Šereš M, Breier A, Sulová Z. The roles of microRNAs in cancer multidrug resistance. Cancers. 2022;14(4):1090.

Article  PubMed  PubMed Central  Google Scholar 

Gulia S, Chandra P, Das A. The prognosis of Cancer depends on the interplay of Autophagy, apoptosis, and Anoikis within the Tumor Microenvironment. Cell Biochem Biophys. 2023;81(4):621–58.

Article  PubMed  CAS  Google Scholar 

Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. Int J Mol Sci. 2021;22(13):7156.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, et al. miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother. 2014;68(8):935–42.

Article  PubMed  CAS  Google Scholar 

Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J cancer Res. 2017;7(6):1350.

PubMed  PubMed Central  CAS  Google Scholar 

Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11:1–24.

Article  Google Scholar 

Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010;126(1):2–10.

Article  PubMed  CAS  Google Scholar 

Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 2022;8(9).

An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sinica B. 2017;7(1):38–51.

Article  Google Scholar 

Gulyaeva LF, Kushlinskiy NE. Regulatory mechanisms of microRNA expression. J Translational Med. 2016;14(1):143.

Article  Google Scholar 

Wang S, Li M-Y, Liu Y, Vlantis AC, Chan JY, Xue L, et al. The role of microRNA in cisplatin resistance or sensitivity. Expert Opin Ther Targets. 2020;24(9):885–97.

Article  PubMed  Google Scholar 

Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93–110.

Chen Y, McCarthy D, Ritchie M, Robinson M, Smyth G, Hall E. edgeR: differential analysis of sequence read count data user’s guide. R Packag. 2020(June):1–121.

Law CW, Alhamdoosh M, Su S, Dong X, Tian L, Smyth GK, et al. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Research. 2016;5. Version 3.

Fattahi Dolatabadi N, Dehghani A, Shahand E, Yazdanshenas M, Tabatabaeian H, Zamani A, et al. The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. Hum Cell. 2020;33(4):1229–39.

Article  PubMed  CAS  Google Scholar 

Kumar P, Nagarajan A, Uchil P. Analysis of cell viability by the MTT assay. Cold Spring Harbor Protoc. 2018;2018(6):pdbprot095505.

Article  Google Scholar 

Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genom. 2005;21(3):389–95.

Article  CAS  Google Scholar 

Jafari N, Najafabadi AN, Hamzei B, Ataee N, Ghasemi Z, Sadeghian-Rizi T, et al. ESRG, LINC00518 and PWRN1 are newly-identified deregulated lncRNAs in colorectal cancer. Exp Mol Pathol. 2022;124:104732.

Article  PubMed  CAS  Google Scholar 

Motulsky H. Prism 5 statistics guide, 2007. GraphPad Software. 2007;31(1):39–42.

Zhou H, Feng B, Abudoureyimu M, Lai Y, Lin X, Tian C, et al. The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer. Life Sci. 2020;261:118362.

Article  PubMed  CAS  Google Scholar 

Barbato S, Solaini G, Fabbri M. MicroRNAs in oncogenesis and tumor suppression. Int Rev cell Mol Biology. 2017;333:229–68.

Article  CAS  Google Scholar 

Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang W, Ma J, Zhou W, Cao B, Zhou X, Yang Z, et al. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets. 2017;21(11):1063–75.

Article  PubMed  CAS  Google Scholar 

Fuller RN, Vallejos PA, Kabagwira J, Liu T, Wang C, Wall NR. miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR. Front Genet. 2024;15:1393353.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Ma D, Kang H, Zhao J, Yang M. Long noncoding RNA LINC01287 promotes proliferation and inhibits apoptosis of lung adenocarcinoma cells via the miR-3529‐5p/RNASEH2A axis under the competitive endogenous RNA pattern. Environ Toxicol. 2021;36(10):2093–104.

Article  PubMed  CAS  Google Scholar 

Weng Z, Peng J, Wu W, Zhang C, Zhao J, Gao H. Downregulation of PART1 inhibits proliferation and differentiation of Hep3B cells by Targeting hsa-miR‐3529‐3p/FOXC2 Axis. J Oncol. 2021;2021(1):7792223.

PubMed  PubMed Central  Google Scholar 

Ma J, Shi Y, Lu Q, Huang D. F2RL3 regulates epithelial-mesenchymal transition and angiogenesis in gastric Cancer through the Rap1/MAPK signaling pathway. Front Bioscience-Landmark. 2024;29(5):177.